Worth reading
54Recurring
Scored from 5 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-58.6
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)2025年6月1日〜2025年11月30日ConsolidatedJapanese GAAPNet Sales30,645¥ millionYear on year -2.3%Progress 45.3%
Operating profit216¥ millionYear on year -58.6%Progress 36.6%
Ordinary income297¥ millionYear on year -46.1%Progress 47.0%
Net income attributable to owners of the parent134¥ millionYear on year -60.3%Progress 37.9%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥53.28
Financial position at period-end
Total assets25,961¥ million
of which net assets 8,912 ¥ millionEquity ratio 34.3%vs. prior year-end +1.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-1,439
Investment-615
Financials-337
Net change-2,391
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥3,306 million
Segment revenueMedical device sales ¥30,670 million (YoY -2.2%), Medical Equipment Manufacturing and Sales ¥104 million (YoY -8.2%), Medical Mall Business ¥36 million (YoY +3.5%)
Segment profitMedical device sales ¥834 million (YoY -25.9%), Medical Equipment Manufacturing and Sales ¥-111 million, Medical Mall Business ¥4 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥67,647 million (YoY +4.9%)
Operating profit¥590 million (YoY -29.6%)
Ordinary income¥632 million (YoY -30.5%)
Net income¥354 million (YoY -42.6%)
Annual Dividend Forecast¥75 → ¥70
Factors Behind Changes in Business Performance
医療機器消耗品の需要は検査・手術件数の増加により増加したものの、医療機関の設備投資需要が前年同期より減少し、売上高が減少した。利益面では、売上総利益の減少と人件費等の販売費及び一般管理費の増加により営業利益、経常利益、親会社株主に帰属する中間純利益が減少した。
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 1 / Company name New Not disclosed / Excluded 株式会社イーディライト
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Loss on sale of shares in a subsidiary ¥2 million
Depreciation and amortization¥93 million
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone (対象者：Not disclosed)
Issued Shares at Period-End2,553,000
Treasury Shares at Period-End60,847
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年6月1日〜2025年11月30日 |
| Net Sales | ¥30,645 million (YoY -2.3%) |
| Operating profit | ¥216 million (YoY -58.6%) |
| Ordinary income | ¥297 million (YoY -46.1%) |
| Profit attributable to owners of the parent | ¥134 million (YoY -60.3%) |
| Net income per share | ¥53.28 |
| Equity ratio | End of the current fiscal period 34.3 / End of previous period 32.6 |
| Total assets | ¥25,961 million |
| Net assets | ¥8,912 million |
| Cash flows from operating activities | ¥-1,439 million |
| Cash flows from investing activities | ¥-615 million |
| Cash flows from financing activities | ¥-337 million |
| Cash and cash equivalents at end of period | ¥3,306 million |
| Full-year earnings forecast | Net Sales ¥67,647 million (YoY +4.9%) / Operating profit ¥590 million (YoY -29.6%) / Ordinary income ¥632 million (YoY -30.5%) / Net income ¥354 million (YoY -42.6%) |
| Annual Dividend Forecast | ¥75 → ¥70 |
| Segment revenue | Medical device sales ¥30,670 million (YoY -2.2%), Medical Equipment Manufacturing and Sales ¥104 million (YoY -8.2%), Medical Mall Business ¥36 million (YoY +3.5%) |
| Segment profit | Medical device sales ¥834 million (YoY -25.9%), Medical Equipment Manufacturing and Sales ¥-111 million, Medical Mall Business ¥4 million |
| Depreciation and amortization | ¥93 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on sale of shares in a subsidiary ¥2 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 1 / Company name New Not disclosed / Excluded 株式会社イーディライト |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 2,553,000 |
| Treasury Shares at Period-End | 60,847 |
| Factors Behind Changes in Business Performance | 医療機器消耗品の需要は検査・手術件数の増加により増加したものの、医療機関の設備投資需要が前年同期より減少し、売上高が減少した。利益面では、売上総利益の減少と人件費等の販売費及び一般管理費の増加により営業利益、経常利益、親会社株主に帰属する中間純利益が減少した。 |
Items this document does not state (8)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.医療機関の設備投資需要が前年同期より減少したことにより売上高が減少し、売上減少に伴う売上総利益の減少と、人件費等の販売費及び一般管理費の増加により利益が減少した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.